Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review

Stefano Arcangeli; Marta Scorsetti; Filippo Alongi

doi:10.1016/j.critrevonc.2011.11.009

Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review

Stefano Arcangeli, Marta Scorsetti, Filippo Alongi

Istituto Clinico Humanitas

Research output: Contribution to journal › Article

Abstract

Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.

Original language	English
Pages (from-to)	101-108
Number of pages	8
Journal	Critical Reviews in Oncology/Hematology
Volume	84
Issue number	1
DOIs	https://doi.org/10.1016/j.critrevonc.2011.11.009
Publication status	Published - Oct 2012

Keywords

Hypofractionation
Prostate cancer
Stereotactic body radiation therapy (SBRT)

ASJC Scopus subject areas

Oncology
Hematology
Geriatrics and Gerontology

Access to Document

10.1016/j.critrevonc.2011.11.009

Fingerprint Dive into the research topics of 'Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review'. Together they form a unique fingerprint.

Cite this

Arcangeli, S., Scorsetti, M., & Alongi, F. (2012). Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critical Reviews in Oncology/Hematology, 84(1), 101-108. https://doi.org/10.1016/j.critrevonc.2011.11.009

@article{a25c862c93894833a8f041af3c57075a,

title = "Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review",

abstract = "Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.",

keywords = "Hypofractionation, Prostate cancer, Stereotactic body radiation therapy (SBRT)",

author = "Stefano Arcangeli and Marta Scorsetti and Filippo Alongi",

year = "2012",

month = oct,

doi = "10.1016/j.critrevonc.2011.11.009",

language = "English",

volume = "84",

pages = "101--108",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review

AU - Arcangeli, Stefano

AU - Scorsetti, Marta

AU - Alongi, Filippo

PY - 2012/10

Y1 - 2012/10

N2 - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.

AB - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.

KW - Hypofractionation

KW - Prostate cancer

KW - Stereotactic body radiation therapy (SBRT)

UR - http://www.scopus.com/inward/record.url?scp=84866483298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866483298&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.11.009

DO - 10.1016/j.critrevonc.2011.11.009

M3 - Article

C2 - 22257653

AN - SCOPUS:84866483298

VL - 84

SP - 101

EP - 108

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -